Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Erhardt (NPI 1467870212)

Field	Value
Entity Type	Individual
Organization	Daniel Erhardt
Address	1715 Iron Horse Dr Ste 150
City	Longmont
State	CO
ZIP	80501
Taxonomy	Rheumatology Physician
NPI Enumerated	March 30, 2014

Payer Source	Total Paid
Medicare	$547.9K
Medicaid	$0

Key Findings

This provider is focused on infusion-based rheumatology care: the top revenue codes are biologic drug administrations (J0129 abatacept, J1745 infliximab, J9312 rituximab) and related infusion services, indicating the practice primarily delivers infused specialty medications rather than office-based E/M encounters. The presence of chemotherapy/infusion administration codes such as 96413 and 96365 and infusion supplies (J7050) further supports an infusion-centric service line consistent with rheumatology infusion suites.

Medicare revenue is $547.9K and there is no Medicaid billing on file, which makes this provider effectively single-payer (Medicare) in the available claims data and means Medicaid does not contribute to the provider’s recorded lifetime revenue. Analysts should treat the entity as Medicare-dependent for public payer volume and reimbursement benchmarking.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 69.3% of total Medicare revenue, signaling that a small set of biologic infusion codes (J0129, J1745, J9312) drive most Medicare income. This concentration implies business risk if prescribing patterns, reimbursement, or patient mix for these high-cost injectables change.

Competitive standing on individual infusion drugs is mixed. For J0129 (abatacept) the provider ranks #932 of 1221 (23rd percentile), which places them below many peers in national volume for that drug and suggests modest market share; for J1745 (infliximab) the provider ranks #440 of 1352 (67th percentile), indicating above-average national activity with this agent; for J9312 (rituximab) the provider ranks #283 of 317 (10th percentile), a relatively low national standing for that code. These percentile positions imply strength with infliximab but limited national presence for abatacept and rituximab.

Payment and utilization patterns show reliance on relatively high-claim volumes for certain J-codes: J0129 (4.6K claims, $157.3K revenue) and J1745 (4.4K claims, $114.4K revenue) each represent large claim counts compared with most non-drug E/M codes, while traditional office visits (e.g., 99212, 99213) produce minimal revenue. This mix indicates the practice’s throughput and billing operations are oriented toward medication administration visits rather than routine clinic visits.

Tenure: the provider’s NPI was enumerated on 2014-03-30 (~12 years ago), indicating a relatively established practice history that can support sustained infusion operations and credentialing with payers. This degree of tenure is consistent with having accumulated the reported lifetime Medicare revenue profile.

There are no Medicaid CPT/HCPCS codes on file, so there is no in-state Medicaid code-level benchmarking to assess; absence of Medicaid billing could reflect provider practice decisions, payer contracting choices, or a patient panel skewed toward Medicare-aged beneficiaries. Analysts should flag this single-payer footprint when modeling payer mix, network adequacy, or access for Medicaid populations.

Among lower-revenue codes, several infusion-related add-ons and care coordination codes appear at modest volumes (96415, 96365, 99490), showing that the practice bills for infusion time and chronic care management in addition to drug supplies. These supporting services contribute incremental revenue but do not substantially diversify the revenue base away from the core biologic J-codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	4,630	$30	$157.3K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	4,400	$30	$114.4K
J9312	Injection, rituximab, 10 mg	1,700	$60	$107.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	5,700	$10	$57K
J0897	Injection, denosumab, 1 mg	1,920	$20	$36.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	160	$110	$16.6K
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	720	$20	$15.1K
J1201	Injection, cetirizine hydrochloride, 0.5 mg	800	$10	$9.6K
99212	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,…	180	$40	$6.7K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	110	$50	$5.9K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

Daniel Erhardt — 1 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	7	30	6,280	$30	$250.4K
J9312	2	10	3,000	$60	$193.6K
J1745	4	40	3,180	$30	$110.6K
J1602	5	20	8,100	$10	$108.9K
J0897	36	140	2,580	$20	$68.8K
Q5121	1	10	1,720	$20	$34.5K
96413	18	140	130	$100	$19.7K
96365	32	170	100	$50	$9.5K
99490	30	320	110	$40	$7.8K
J1201	1	10	680	$10	$7.6K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Erhardt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Denver Health And Hospital Authority	CO	General Practice Physician	$0	$95M
Denver Health And Hospital Authority	CO	General Acute Care Hospital	$0	$77.1M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$68.5M
Denver Health And Hospital Authority	CO	Ambulance	$3.4M	$46.3M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$40.3M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$29.4M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$28.2M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$25.5M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$17.4M
Denver Health And Hospital Authority	CO	Federally Qualified Health Center (FQHC)	$0	$15.2M

Nearby Providers

Other providers in the same ZIP code as Daniel Erhardt, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sample Supports	CO	Community/Behavioral Health Agency	$0	$105.8M
Salud Family Health	CO	Federally Qualified Health Center (FQHC)	$0	$25.7M
Carmel Community Living Corporation	CO	Developmentally Disabled Services Day Training Agency	$0	$21.2M
Elevated Supports, LLC	CO	Respite Care	$0	$14.6M
Hero Dental Of Longmont PC	CO	General Practice Dentistry	$0	$13M
Hopelight Medical Clinic	CO	Health Service Clinic/Center	$0	$12.3M
Hero Vision Of Longmont, LLC	CO	Optometrist	$0	$11.9M
Senior Housing Options, Inc.	CO	Assisted Living Facility	$0	$5.7M
Vcphcs X, LLC	CO	Substance Use Disorder Rehabilitation Clinic/Center	$156.9K	$5.3M
Longmont United Hospital	CO	General Acute Care Hospital	$0	$5.2M

Daniel Erhardt — Billing Profile & Reimbursement Data

Sign up for Daniel Erhardt — Billing Profile & Reimbursement Data policy alerts

Daniel Erhardt — Billing Profile & Reimbursement Data

Sign up for Daniel Erhardt — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References